SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cyclo Therapeutics, Inc. (CYTH) , forward earnings yield 48.54%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (90/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+31.8%).
- Forward P/E 2.1
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $0.95 (+31.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CYTH
Valuation Multiples
P/E (TTM)0.0
Forward P/E2.1
PEG Ratio0.01
Forward PEG0.01
P/B Ratio0.00
P/S Ratio10.93
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.23
Forward EPS (Est.)$0.35
Book Value / Share$0.00
Revenue / Share$0.07
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield48.54%
Dividend Yield0.00%
Analyst Target$0.95 (+31.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-1.17 |
$1.57M |
$-592.69K |
-37.8% |
| 2015 |
$-4.54 |
$950.46K |
$-2.55M |
-268.4% |
| 2016 |
$-6.67 |
$1.5M |
$-4.22M |
-281% |
| 2017 |
$-5.32 |
$1.24M |
$-3.83M |
-309.7% |
| 2018 |
$-5.20 |
$1.01M |
$-4.26M |
-420.7% |
| 2019 |
$-7.09 |
$1.01M |
$-7.67M |
-761.9% |
| 2020 |
$-5.58 |
$903.38K |
$-8.92M |
-987.7% |
| 2021 |
$-2.25 |
$1.59M |
$-14.31M |
-902.1% |
| 2022 |
$-1.81 |
$1.38M |
$-15.28M |
-1110.7% |
| 2023 |
$-1.23 |
$1.08M |
$-20.06M |
-1863.4% |
